Evidence map›Paper›PMID 41656939›Full record

ArticleJournal of extracellular vesicles2026

Tissue-Derived Extracellular Vesicles Define Diagnostic Biomarkers for Renal Cell Carcinoma.

Xinrui Wu, Jiale Zhou, Chen Jiang, Wenjin Chen, Zehong Peng, Tianyang Wu, Yang Ge, Xinxing Du, Cong Hu, Xiaorong Wu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xinrui WuDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0000-0002-6077-4855
Jiale ZhouDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chen JiangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Wenjin ChenDepartment of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zehong PengDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Tianyang WuDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yang GeDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xinxing DuDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Cong HuDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiaorong WuDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jiwei HuangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jin ZhangDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xingang CuiDepartment of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.ORCID https://orcid.org/0000-0002-0920-9439
Wei XueDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yonghui ChenDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Liang DongDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Funding

Physician-Scientist Development Award from Shanghai Immune Therapy InstituteShanghai Jiao Tong UniversityShanghai Jiao Tong University School of Medicine Institute of Molecular Medicine Clinical+ Excellence Program 2025ZYA-001Shanghai Municipal Health Commission 2022YQ014Shanghai Professional Technical Service Platform 23DZ2291000Shanghai Rising-Star Program 23QA1405900Shanghai Top Priority Research Center Project 2023ZZ02014Shanghal High level Local universities Construction Program
6 · The paper itself

Abstract

Tissue-derived extracellular vesicles (Ti-EVs) play a crucial role in tumour progression, but their value as differential diagnostic markers for various renal cell carcinoma (RCC) subtypes remains uncertain. Through analysis of paired tumour and normal tissues, along with their corresponding Ti-EVs, we identified NEAT1 and MMP15 as markers for papillary RCC (pRCC); DSG2 and AC026888.1 for chromophobe RCC (chRCC); NDUFA4L2, SERPINA1, VEGFA, EGLN3, CPE and C6orf223 for low-grade clear cell RCC (low-grade ccRCC); and NDUFA4L2, APOC1, TGFBI and LINC00887 for high-grade ccRCC (high-grade ccRCC). In an external validation cohort, an area under the curve (AUC) of 0.922 for low-grade ccRCC detection and 0.874 for high-grade ccRCC detection was achieved, respectively, using urinary EVs. Furthermore, integrating single-cell sequencing data revealed that SERPINA1 and VEGFA in low-grade ccRCC, and APOC1 and TGFBI in high-grade ccRCC, were derived from tumour-associated macrophages, whereas NDUFA4L2 originated from cancer cells in both low- and high-grade ccRCC.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellExtracellular VesiclesKidney NeoplasmsFemaleHumansMaleVascular Endothelial Growth Factor ABiomarkers, TumorVascular Endothelial Growth Factor Aextracellular vesiclesrenal cell carcinomasingle‐cell sequencing

Identifiers

PMID41656939
PMCPMC12884001

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.